RA
OXFD

Royce & Associates’s Oxford Immunotec Global PLC Ordinary Shares OXFD Stock Holding History

Royce & Associates’s Portfolio OXFD Stock Details OXFD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,200
Closed -$68K – 1211
2020
Q2 		$68K Hold
5,200
– – ﹤0.01% 1006
2020
Q1 		$48K Hold
5,200
– – ﹤0.01% 1015
2019
Q4 		$86K Buy
+5,200
New +$84.3K ﹤0.01% 999

Other funds holding OXFD

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $432M AUM 42.58% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royce & Associates's OXFD Position: Q3 2020 in Review

Royce & Associates sold out of Oxford Immunotec Global PLC Ordinary Shares (OXFD) in Q3 2020, closing a stake of 5,200 shares — an estimated $68K sold.

Royce & Associates first reported a position in OXFD in Q4 2019 and held it in 3 quarters. The position peaked at $86K in Q4 2019. 71 funds tracked by Wall St. Rank hold OXFD as of Q3 2020.

  • Royce & Associates reported no remaining Oxford Immunotec Global PLC Ordinary Shares position as of Q3 2020 after selling out during the quarter.
  • Royce & Associates sold 5,200 Oxford Immunotec Global PLC Ordinary Shares shares in Q3 2020, an estimated $68K.
  • Royce & Associates first reported a position in Oxford Immunotec Global PLC Ordinary Shares in Q4 2019 and held it in 3 quarters.
  • Royce & Associates's Oxford Immunotec Global PLC Ordinary Shares position peaked at $86K in Q4 2019.
  • 71 funds tracked by Wall St. Rank held Oxford Immunotec Global PLC Ordinary Shares as of Q3 2020.

Based on Royce & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.